OncoMatch/Clinical Trials/NCT07785154
A Registry-study of ELZONRIS in Participants With BPDCN
Is NCT07785154 recruiting? Yes, currently enrolling (Sep 2026). Studying Tagraxofusp for blastic plasmacytoid dendritic cell neoplasm (bpdcn).
Treatment: Tagraxofusp — The main goal of this registry study is to investigate the effectiveness and safety of tagraxofusp in the treatment of adult participants with BPDCN in the real-world clinical practice setting.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Biomarker criteria
Required: IL3RA expression (testing required; no eligibility threshold specified)
biomarkers (inclusive of CD123, CD4, and CD56)
Required: CD4 expression (testing required; no eligibility threshold specified)
biomarkers (inclusive of CD123, CD4, and CD56)
Required: CD56 expression (testing required; no eligibility threshold specified)
biomarkers (inclusive of CD123, CD4, and CD56)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07785154 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require IL3RA?
Yes, IL3RA expression is a required biomarker for enrollment.
Does this trial require CD4?
Yes, CD4 expression is a required biomarker for enrollment.
Does this trial require CD56?
Yes, CD56 expression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify